Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cells for Bronchopulmonary Dysplasia in Preterm Infants
NCT03378063Phase 1Withdrawn
- Start
- Nov 2017
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cells in bronchopulmonary dysplasia (BPD) (2 arms). Primary endpoint: Death at 2 years. Planned start Nov 2017; status: withdrawn.
02
Drugs
mesenchymal stem cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03378063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378063.